
Zenotech Laboratories Ltd is Rated Strong Sell
2026-11-11 10:10:24Zenotech Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read More
Zenotech Laboratories Ltd Valuation Shifts Signal Elevated Risk Amid Sector Challenges
2026-10-30 08:01:53Zenotech Laboratories Ltd has experienced a marked deterioration in its valuation parameters, shifting from a previously expensive profile to a risky classification. This change, coupled with negative returns relative to the Sensex and underwhelming profitability metrics, raises significant concerns for investors within the Pharmaceuticals & Biotechnology sector.
Read More
Zenotech Laboratories Ltd is Rated Strong Sell
2026-10-28 10:10:44Zenotech Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 24 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 28 October 2026, providing investors with the latest perspective on the company’s position.
Read More
Zenotech Laboratories Ltd is Rated Strong Sell
2026-10-17 10:10:31Zenotech Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 24 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 17 October 2026, providing investors with the latest view of the company’s position.
Read More
Zenotech Laboratories Ltd is Rated Strong Sell
2026-10-06 10:10:36Zenotech Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 October 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Read More
Zenotech Laboratories Ltd Forms Death Cross, Signalling Potential Bearish Trend
2026-09-30 18:00:42Zenotech Laboratories Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential deterioration in the stock’s trend and raises concerns about sustained bearish momentum in the Pharmaceuticals & Biotechnology sector.
Read More
Zenotech Laboratories Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals
2026-09-25 08:16:56Zenotech Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its quality, valuation, financial trends, and technical indicators. The downgrade reflects deteriorating fundamentals, negative earnings performance, and a shift towards bearish technical signals, signalling heightened caution for investors in this micro-cap pharmaceutical stock.
Read More
Zenotech Laboratories Ltd is Rated Sell
2026-09-24 10:11:20Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 September 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 24 September 2026, providing investors with an up-to-date analysis of the company’s standing.
Read More
Zenotech Laboratories Ltd is Rated Sell
2026-09-13 10:10:04Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreBoard Meeting Outcome for Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026.
28-Oct-2026 | Source : BSESubmission of Unaudited Financial Results of the Company for the quarter and half year ended September 30 2026.
Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026
28-Oct-2026 | Source : BSEApproval for Unaudited Financial Results of the Company for the quarter and half year ended September 30 2026.
Board Meeting Intimation for Considering And Approving Unaudited Standalone Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026.
17-Oct-2026 | Source : BSEZenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 inter alia to consider and approve Unaudited Standalone Financial Results for the quarter and half year ended September 30 2026.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Zenotech Laboratories Ltd has announced 17:22 rights issue, ex-date: 01 Jun 17